Хайлтын үр дүнгүүд - Patalano, Francesco
- 25-н 1 - 20 үр дүнгүүдийг харуулж байна
- Дараагийн хуудас руу очих
-
1
-
2
-
3
-
4
-
5
-
6
Efficacy and safety of twice-daily glycopyrrolate in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation: the GEM1 study -н LaForce, Craig, Feldman, Gregory, Spangenthal, Selwyn, Eckert, Joerg H, Henley, Michelle, Patalano, Francesco, D’Andrea, Peter
Хэвлэсэн 2016текст -
7
Indacaterol/glycopyrronium in symptomatic patients with COPD (GOLD B and GOLD D) versus salmeterol/fluticasone: ILLUMINATE/LANTERN pooled analysis -н Vogelmeier, Claus, Zhong, Nanshan, Humphries, Michael J, Mezzi, Karen, Fogel, Robert, Bader, Giovanni, Patalano, Francesco, Banerji, Donald
Хэвлэсэн 2016текст -
8
Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study -н Wedzicha, Jadwiga A, Zhong, Nanshan, Ichinose, Masakazu, Humphries, Michael, Fogel, Robert, Thach, Chau, Patalano, Francesco, Banerji, Donald
Хэвлэсэн 2017текст -
9
Long-Term Maintenance Bronchodilation With Indacaterol/Glycopyrrolate Versus Indacaterol in Moderate-to-Severe COPD Patients: The FLIGHT 3 Study -н Ferguson, Gary T., Taylor, Angel Fowler, Thach, Chau, Wang, Qian, Schubert-Tennigkeit, Agnes A., Patalano, Francesco, Banerji, Donald
Хэвлэсэн 2016текст -
10
Evaluation of the content validity of patient-reported outcome (PRO) instruments developed for use with individuals with phakic presbyopia, including the Near Activity Visual Quest... -н Bentley, Sarah, Findley, Amy, Chiva-Razavi, Sima, Naujoks, Christel, Patalano, Francesco, Johnson, Chloe, Arbuckle, Rob, Wolffsohn, James S.
Хэвлэсэн 2021текст -
11
Understanding the visual function symptoms and associated functional impacts of phakic presbyopia -н Bentley, Sarah, Findley, Amy, Chiva-Razavi, Sima, Naujoks, Christel, Patalano, Francesco, Johnson, Chloe, Arbuckle, Rob, Wolffsohn, James S.
Хэвлэсэн 2021текст -
12
LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD -н Zhong, Nanshan, Wang, Changzheng, Zhou, Xiangdong, Zhang, Nuofu, Humphries, Michael, Wang, Linda, Thach, Chau, Patalano, Francesco, Banerji, Donald
Хэвлэсэн 2015текст -
13
LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis -н Rodrigo, Gustavo J, Price, David, Anzueto, Antonio, Singh, Dave, Altman, Pablo, Bader, Giovanni, Patalano, Francesco, Fogel, Robert, Kostikas, Konstantinos
Хэвлэсэн 2017текст -
14
Efficacy and Safety of Twice-Daily Glycopyrrolate Versus Placebo in Patients With COPD: The GEM2 Study -н Kerwin, Edward, Siler, Thomas M., Korenblat, Phillip, White, Alexander, Eckert, Joerg H., Henley, Michelle, Patalano, Francesco, D’Andrea, Peter
Хэвлэсэн 2016текст -
15
Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study -н Anzueto, Antonio R., Kostikas, Konstantinos, Mezzi, Karen, Shen, Steven, Larbig, Michael, Patalano, Francesco, Fogel, Robert, Banerji, Donald, Wedzicha, Jadwiga A.
Хэвлэсэн 2018текст -
16
Patient-reported outcome measures in presbyopia: a literature review -н Sharma, Garima, Chiva-Razavi, Sima, Viriato, Daniel, Naujoks, Christel, Patalano, Francesco, Bentley, Sarah, Findley, Amy, Johnson, Chloe, Arbuckle, Rob, Wolffsohn, James
Хэвлэсэн 2020текст -
17
Impact of baseline symptoms and health status on COPD exacerbations in the FLAME study -н Mackay, Alexander J., Kostikas, Konstantinos, Roche, Nicolas, Frent, Stefan-Marian, Olsson, Petter, Pfister, Pascal, Gupta, Pritam, Patalano, Francesco, Banerji, Donald, Wedzicha, Jadwiga A.
Хэвлэсэн 2020текст -
18
Early Clinically Important Improvement (ECII) and Exacerbation Outcomes in COPD Patients -н Kostikas, Konstantinos, Mackay, Alexander J, Vogelmeier, Claus F, Frent, Stefan-Marian, Gupta, Pritam, Banerji, Donald, Patalano, Francesco, Pfister, Pascal J, Wedzicha, Jadwiga A
Хэвлэсэн 2020текст -
19
Treatment response in COPD: does FEV(1) say it all? A post hoc analysis of the CRYSTAL study -н Kostikas, Konstantinos, Greulich, Timm, Mackay, Alexander J., Lossi, Nadine S., Aalamian-Mattheis, Maryam, Nunez, Xavier, Pagano, Veronica A., Patalano, Francesco, Clemens, Andreas, Vogelmeier, Claus F.
Хэвлэсэн 2019текст -
20
Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of... -н Greulich, Timm, Kostikas, Konstantinos, Gaga, Mina, Aalamian-Mattheis, Maryam, Lossi, Nadine S, Patalano, Francesco, Nunez, Xavier, Pagano, Veronica A, Fogel, Robert, Vogelmeier, Claus F, Clemens, Andreas
Хэвлэсэн 2018текст